Updated:
Flexion Therapeutics Inc
Flexion Therapeutics Inc is identified in the retained SEC EDGAR snapshot dated 2026-10-14. Its SEC Central Index Key is 0001419600, and its reported...
Overview
Flexion Therapeutics Inc is identified in the retained SEC EDGAR snapshot dated 2026-10-14. Its SEC Central Index Key is 0001419600, and its reported industry is Pharmaceutical Preparations. In 10-K filed on 2021-03-10, it reported annual revenue of USD 85,552,000; net income of USD -113,706,000; total assets of USD 251,926,000 for the fiscal period ended 2020-12-31. The financial history preserves reporting periods, currencies, filing accessions and source provenance. Figures are reported filing data, rather than real-time estimates.
Company overview
- Legal name
- Flexion Therapeutics Inc
- Classification
- Company
- Industry (SIC)
- 2834 — Pharmaceutical Preparations
- Headquarters
- Burlington, MA, United States
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 0001419600
Financials
Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.
| Fiscal year | Period end | Revenue | Net income | Total assets | Cash and equivalents | Operating cash flow |
|---|---|---|---|---|---|---|
| FY2020USD | $85.6M | -$113.7M | $251.9M | $107.7M | -$70.6M | |
| FY2019USD | $73.0M | -$149.8M | $217.6M | $82.3M | -$148.8M | |
| FY2018USD | $22.5M | -$169.7M | $295.8M | $87.2M | -$160.4M | |
| FY2017USD | — | -$137.5M | $441.3M | $127.8M | — |
Recent SEC filings
| Form | Filed | Period | Filing |
|---|---|---|---|
| SC 13G | — | SC 13G/A | |
| 8-K | FORM 8-K | ||
| 10-Q | 10-Q | ||
| 8-K | FORM 8-K | ||
| 10-Q | 10-Q | ||
| 8-K | 8-K | ||
| 8-K | 8-K | ||
| 8-K | 8-K | ||
| 10-Q | 10-Q | ||
| 8-K | 8-K | ||
| 8-K | 8-K | ||
| DEF 14A | DEF 14A |
Profile maintained by Altss. Updated: . To correct this record or make a privacy request, send the page URL and your evidence to privacy@altss.com; corrections are free.
Research Flexion Therapeutics Inc in Altss
Track this company’s investors, transactions and relationships in Altss.